<div id="readability-page-1"><div><p>Mabwell announced that the first patient has been dosed in the Phase I/II clinical trial of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&amp;D code: 7MW4911) for advanced solid tumors. This Phase I/II clinical trial (CTR20254163) aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of 7MW4911 in patients with advanced solid tumors. Previously, 7MW4911 had received IND clearance from FDA to initiate a Phase I/II clinical trial for advanced colorectal cancer and other advanced gastrointestinal tumors (NCT07216560).</p><p>7MW4911 is a novel CDH17-targeted ADC developed by Mabwell based on its proprietary IDDC?? platform. It is composed of a highly specific CDH17 monoclonal antibody capable of efficient internalization into tumor cells, a novel cleavable linker with high plasma stability, and a proprietary DNA topoisomerase I inhibitor payload, MF-6, specifically designed to overcome the multidrug resistance.</p><p>Preclinical studies demonstrated that 7MW4911 exhibited potent antitumor activity in CDX/PDX models of various gastrointestinal tumors. In multidrug-resistant models, its antitumor effect was significantly superior to MMAE/DXd-based ADCs, and it was able to reverse tumor progression following treatment with such ADCs, highlighting its advantage in treating resistant tumors. Relevant research findings have been published in the 2025 AACR and the internationally renowned journal Cell Reports Medicine (July 2025).</p></div></div>

邁威生物-U

<p>邁威生物-U 宣佈其新型 CDH17 靶向 ADC 7MW4911 在針對晚期實體瘤的 I/II 期臨牀試驗中首次給藥。該試驗旨在評估 7MW4911 的安全性、耐受性、藥代動力學和初步療效。前臨牀研究顯示其具有強大的抗腫瘤活性，特別是在多藥耐藥模型中。7MW4911 之前已獲得 FDA 的新藥臨牀試驗（IND）批准，用於晚期結直腸和胃腸腫瘤</p>

邁威生物-U 宣佈首例患者接受新型 CDH17 靶向 ADC 藥物 7MW4911 的給藥